Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman LLP Successfully Represents EF Hutton in $4 Million Offering of TC Biopharm (Holdings) PLC American Depositary Shares (ADS)

Lucosky Brookman congratulates its client, EF Hutton, division of Benchmark Investments, LLC, on its successful $4 million underwritten public offering of American Depositary Shares (ADS) of TC Biopharm (Holdings) PLC (Nasdaq: TCBP; TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications. The offering  consists of 10,000,000 ADSs, each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses.  In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Lucosky Brookman represented EF Hutton in its capacity as sole book-running manager.